A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast
Lawrence J. Solin, Robert P. Gray, Frederick L. Baehner et al. · JNCI Journal of the National Cancer Institute · 2013
BACKGROUND: For women with ductal carcinoma in situ (DCIS) of the breast, the risk of developing an ipsilateral breast event (IBE; defined as local recurrence of DCIS or invasive carcinoma) after surgical excision without radiation is not well defined by clinical and pathologic characteristics. METHODS: The Oncotype DX breast cancer assay was performed for patients with DCIS treated with surgical excision without radiation in the Eastern Cooperative Oncology Group (ECOG) E5194 study. The association of the prospectively defined DCIS Score (calculated from seven cancer-related genes and five reference genes) with the risk of developing an IBE was analyzed using Cox regression. All statistical tests were two-sided. RESULTS: There were 327 patients with adequate tissue for analysis. The continuous DCIS Score was statistically significantly associated with the risk of developing an IBE (hazard ratio [HR] = 2.31, 95% confidence interval [CI] = 1.15 to 4.49; P = .02) when adjusted for tamoxifen use (prespecified primary analysis) and with invasive IBE (unadjusted HR = 3.68, 95% CI = 1.34 to 9.62; P = .01). For the prespecified DCIS risk groups of low, intermediate, and high, the 10-year risks of developing an IBE were 10.6%, 26.7%, and 25.9%, respectively, and for an invasive IBE, 3.7%, 12.3%, and 19.2%, respectively (both log rank P ≤ .006). In multivariable analyses, factors associated with IBE risk were DCIS Score, tumor size, and menopausal status (all P ≤ .02). CONCLUSIONS: The DCIS Score quantifies IBE risk and invasive IBE risk, complements traditional clinical and pathologic factors, and provides a new clinical tool to improve selecting individualized treatment for women with DCIS who meet the ECOG E5194 criteria.
Cited by 518 works. doi:10.1093/jnci/djt067 Open-access PDF
Authors
- Lawrence J. Solin
- Robert P. Gray
- Frederick L. Baehner
- Steven M. Butler
- Lorie L. Hughes
- CARL N. YOSHIZAWA
- Diana B. Cherbavaz
- Steven Shak
- David L. Page
- George W. Sledge
- Nancy E. Davidson
- James N. Ingle
- Edith A. Perez
- W. C. Wood
- Joseph A. Sparano
- Sunil Badve
References
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
- Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
- Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17.
- The Influence of Margin Width on Local Control of Ductal Carcinoma in Situ of the Breast
- Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial
- Measurement of Gene Expression in Archival Paraffin-Embedded Tissues
- Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17
- Ductal Carcinoma in Situ of the Breast
- A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients
- Risk Factors for Recurrence and Metastasis After Breast-Conserving Therapy for Ductal Carcinoma-In-Situ: Analysis of European Organization for Research and Treatment of Cancer Trial 10853